Startups
We support early-stage biotech and longevity-focused founders that are changing the world. We help these companies gain industrial momentum, raise capital, and shape the future of biotech. Our approach is based on growing the whole ecosystem. We fund companies in complementary industrial sectors, empowering us to build a broad community of biotech innovators that can exchange their expertise and build on each other's successes.
Overview
Location
Switzerland, Ticino, Paradiso
Employees
1-10
Founded date
2016
Mentions in press and media 20
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 27, 2025 | Valink Therapeutics: $11.8 Million Raised To Advance Bispecific ADC Pipeline And Expand U.S. Operations | Valink Therapeutics, a biotechnology company pioneering next-generation oncology therapeutics, announced it has closed an $11.8 million pre-A financing round to accelerate development of its bispecific antibody-drug conjugate (bsADC) pipeli... |
| Oct 20, 2025 | Valink Therapeutics Secures $11.8 Million to Advance Next-Generation Oncology | Valink Therapeutics secured $11.8 million in pre-A funding. This capital accelerates its next-generation oncology pipeline. The company focuses on innovative bispecific antibody-drug conjugates (bsADCs). Its proprietary V-gate technology en... |
| Oct 20, 2025 | Valink Therapeutics: $11.8 Million Pre-A Funding Secured To Advance Next-Generation Oncology Pipeline | Valink Therapeutics, a biotechnology company developing next-generation oncology therapeutics focused on bispecific antibody-drug conjugates (bsADCs) and complementary treatment modalities, announced the successful closing of an $11.8 milli... |
| Oct 20, 2025 | Valink Therapeutics Closes $11.8M Pre-A Financing Round | Valink Therapeutics, Inc., a Cambridge, MA-based biotechnology company developing next-generation oncology therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities for improved patient outcomes,... |
| Oct 7, 2025 | Precision Oncology Pioneer Trogenix Secures Landmark €80M Series A for Curative Cancer Fight | Trogenix, an Edinburgh-based biotech, secured a monumental €80 million Series A funding. This capital empowers its pursuit of curative cancer treatments for aggressive solid tumors. The firm's Odysseus platform uses advanced gene control an... |
| Oct 6, 2025 | Edinburgh-based BioTech Trogenix lands €80 million to accelerate curative cancer treatments | Trogenix Ltd, a Scottish BioTech company dedicated to innovative cancer therapies, announced the completion of its Series A financing, raising €80 million, to advance its pipeline of potentially curative cancer therapies across multiple agg... |
| Oct 6, 2025 | Edin Uni Spinout Trogenix Raises £70M to Treat Aggressive Cancers | University of Edinburgh spinout Trogenix, which is developing curative therapies for aggressive, treatment-resistant cancers, has completed Series A financing of £70 million. The funding will allow the biotech company to rapidly advance its... |
| Mar 11, 2025 | Startup Moldova Summit 2025—Moldova’s Biggest Startup & VC Event—Returns This April | Startup Moldova Summit 2025 is Moldova’s biggest startup/VC gathering The date is April 16th, and the place is Mediacor in Chișinău The Summit’s agenda features global investors, founders, and experts, focusing on startup growth, talent, sc... |
| Dec 3, 2024 | Latvian LongeVC invests in US startup Glyphic Biotechnologies | Latvian fund LongeVC has invested in US-based Glyphic Biotechnologies , which is developing a protein sequencing platform. Founded in New York in 2021 by Daniel Estandian and Joshua Yang, Glyphic Biotechnologies is developing a protein sequ... |
Show more
Reviews 0
FAQ about LongeVC
When was LongeVC founded?
LongeVC was founded in 2016.
What has the press written about LongeVC?
Parsers VC has collected 20 articles mentioning LongeVC, among them “Valink Therapeutics: $11.8 Million Raised To Advance Bispecific ADC Pipeline And Expand U.S. Operations” (Oct 27, 2025) and “Valink Therapeutics Secures $11.8 Million to Advance Next-Generation Oncology” (Oct 20, 2025).
Is LongeVC still active?
Yes, LongeVC is active; its latest activity on Parsers VC dates from Nov 6, 2025.